Outsourced Vaccine Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourced Vaccine Development
The authors discuss how strategic outsourcing to contract manufacturing organizations that have technical and regulatory expertise can add further value during vaccine development.


Pharmaceutical Technology
Volume 33, Issue 7

References

1. Kalorama Information, http://www.kaloramainformation.com/, accessed June 22, 2009.

2. C. Franco, "Billions for Biodefense: Federal Agency Biodefense Funding, FY2008-FY2009," Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, 6 (2), page 131 (2008).

3. PhRMA, "Report on Biotechnology Medicines in Development", 2008, http://www.pharma.org/, accessed June 22, 2009.

4. K.J. Morrow, Jr., "Revamping and Reengineering Existing Technology Can Increase Protein Yield and Efficacy," Gen. Engineer. and Biotechnol. News, 27 (5) 50–54 (2007).

5. Y. Durocher et al., "Scalable serum-free Production of Recombinant adeno-associated Virus Type 2 by Transfection of 293 Suspension cells, Journ. of Virolog. Meth., 144, p. 32 (2007).

6. H.R.G. Clarke, and B.J. Compton, "Comparing Mammalian Expression Systems The First Rate-Limiting Step in Making Products for Clinical Testing," supplement to BioProcess Internat., 6 (11) 24–32 (2008).

7. P. Gagnon, "Monoliths Emerge as Key Purification Methodology," Gen. Engineer. and Biotechnol. News, 28 (14) (2008), http://www.genengnews.com/.

8. C. H. Arnaud, "Analyzing Vaccines," Chem. & Engineer. News, 84 (14), P. 52 (2006).

9. C. Scott, "Formulation Development, Making the Medicine," supplement to BioProcess Internat., 42 (3) 42–56, March 2006.

10. A. Sjolander, J.C. Cox, and I.G. Barr, "ISCOMs: An Adjuvant with Multiple Functions," Jour. of Leukocyte Biol., 64, 713–723 (1998).

11. S. Crossman and J. Lawson, "Considerations for Choosing a CMO," Contract Pharm., 10 (2008), http://www.contractpharma.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here